TY - JOUR T1 - The Amortization of Funding Gene Therapies: Making the “Intangibles” Tangible for Patients JF - medRxiv DO - 10.1101/2021.04.16.21255597 SP - 2021.04.16.21255597 AU - Monique Dabbous AU - Mondher Toumi AU - Steven Simoens AU - Juergen Wasem AU - Yitong Wang AU - José Huerta Osuna AU - Clément François AU - Lieven Annemans AU - Johann-Matthias Graf von der Schulenburg AU - Oriol Sola-Morales AU - Daniel Malone AU - Louis P. Garrison Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/23/2021.04.16.21255597.abstract N2 - Gene replacement therapies (GRTs) are increasingly expected to reach the market. Current healthcare systems are struggling to fund such valuable, costly therapies. GRTs are highly valuable as they extend life through sustained, long-term efficacy or by saving on the costs of a current high-cost standard of care. Some payers have implemented payment models, which do not address the budget impact on the year of acquisition or administration of costly GRTs. This study aims to (1) introduce amortization as an accounting tool within the context of healthcare, specifically for GRTs, (2) present a systematic literature review (SLR) on the amortization or depreciation of pharmaceuticals and medical devices, (3) assess the rationale and feasibility as well as the pros and cons of the amortization of GRTs, and (4) provide recommendations for future steps for the introduction of amortization for GRTs. The limited literature, identified in the SLR, has proposed amortization as a solution for costly, highly valuable GRT funding, but did not fully investigate and detail amortization and its feasibility. This paper further details and illustrates amortization as a promising method for these GRTs by facilitating market and patient access. Current accounting principles and guidelines must evolve to apply amortization to GRTs.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThere was no funding involved in the development of this research and manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData reported is easily available via various databases open access to those who wish to replicate the study. Furthermore, all data and methodology are reported on with full transparency. ER -